Manu Shankar Hari

    Home / Manu Shankar Hari

Manu Shankar Hari

ManuEmail:  manu.shankar-hari@kcl.ac.uk

Address: Guys and St Thomas’ Hospital, London

Region: London

Research type: Clinical, Pre-clinical

  • Research Interests:
  • Role of innate and adaptive immunity in acute organ failure and recovery
  • B lymphocyte and immunoglobulin function in early sepsis related illness
  • Trends in sepsis related outcomes in adults.

Key Techniques: FACS, epidemiology

Keywords:  immunology of sepsis, acute organ failure, epidemiology and study design.

Funding: 

Collaborations: Mervyn Singer

Selected Publications:

  1. Cuello F, Shankar-Hari M, Mayr U, Yin X, Marshall M, Suna G, Willeit P, Langley SR, Jayawardhana T, Zeller T, Terblanche M, Shah AM, Mayr M. Redox-state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis. Mol Cell Proteomics. 2014 Jun 23. pii: mcp.M114.039446. PubMed PMID: 24958171.
  2. Shankar-Hari M, Lord GM. How might a diagnostic microRNA signature be used to speed up the diagnosis of sepsis? Expert Rev Mol Diagn. 2014 Apr;14(3):249-51. doi: 10.1586/14737159.2014.899151. PubMed PMID: 24649814.
  3. Edgeworth JD, Chis Ster I, Wyncoll D, Shankar-Hari M, McKenzie CA. Long-term adherence to a 5 day antibiotic course guideline for treatment of intensive care unit (ICU)-associated Gram-negative infections. J Antimicrob Chemother. 2014 Jun;69(6):1688-94. doi: 10.1093/jac/dku038. Epub 2014 Feb 25. PubMed PMID: 24573413.
  4. Williams SE, Sabir I, Nimmo C, Linton N, Sebag FA, Harrison JL, Wright M, Barrett NA, Shankar-Hari M, O’Neill MD. Quantitative assessment of the effects of therapeutic hypothermia on early repolarization in idiopathic ventricular fibrillation survivors: a 7-year cohort study. Circ Arrhythm Electrophysiol. 2014 Feb;7(1):120-6. doi: 10.1161/CIRCEP.113.000555. Epub 2014 Jan 1. PubMe PMID:24382408.
  5. Shankar-Hari M, Kruger PS, Di Gangi S, Scales DC, Perkins GD, McAuley, DF,Terblanche M. Statin therapy in critical illness: an international survey of intensive care physicians’ opinions, attitudes and practice. BMC Clin Pharmacol. 2012 Jun 28;12:13. doi: 10.1186/1472-6904-12-13. PubMed PMID: 22742644; PubMed Central PMCID: PMC3416708.
  1. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: Immunoglobulin therapy for sepsis – biological plausibility from a critical care perspective. Crit Care. 2012 Dec 12;16(2):206. doi: 10.1186/cc10597. Review. PubMed PMID: 22424150; PubMed Central PMCID: PMC3584720.
  2. Soares MO, Welton NJ, Harrison DA, Peura P, Shankar- Hari M, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16(7):1-186. doi: 10.3310/hta16070. Review. PubMed. PMID:22361003.